Van Diest Capital LLC Makes New $586,000 Investment in Amgen Inc. $AMGN

Van Diest Capital LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,664 shares of the medical research company’s stock, valued at approximately $586,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC raised its position in shares of Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after buying an additional 114 shares in the last quarter. Schnieders Capital Management LLC. raised its position in shares of Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after buying an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC boosted its stake in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after buying an additional 416 shares during the period. Finally, Ieq Capital LLC boosted its stake in Amgen by 5.1% during the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after buying an additional 2,611 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on AMGN shares. Erste Group Bank restated a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Weiss Ratings downgraded Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 15th. The Goldman Sachs Group set a $389.00 price objective on Amgen in a report on Friday, June 5th. Truist Financial upped their price objective on shares of Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a research report on Tuesday, July 7th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $400.00 target price on shares of Amgen in a research note on Wednesday, July 1st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $356.62.

Amgen Stock Up 1.2%

Shares of NASDAQ AMGN opened at $376.04 on Friday. The stock has a market capitalization of $202.95 billion, a P/E ratio of 26.17, a PEG ratio of 3.80 and a beta of 0.41. Amgen Inc. has a one year low of $269.77 and a one year high of $391.29. The firm’s 50 day simple moving average is $351.28 and its two-hundred day simple moving average is $351.80. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the previous year, the business posted $4.90 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts expect that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.